NICORETTE (MINT)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NICORETTE (MINT) (NICORETTE (MINT)).
Nicotine binds to nicotinic acetylcholine receptors (nAChRs) in the brain, stimulating dopamine release in the mesolimbic pathway, which reduces withdrawal symptoms and cravings associated with smoking cessation.
| Metabolism | Primarily hepatic via CYP2A6 (major) and CYP2B6, and also metabolized by aldehyde oxidase. Main metabolite is cotinine. |
| Excretion | Renal: 60-80% as metabolites (cotinine, nicotine N-oxide), 10-20% unchanged; biliary/fecal: <10% |
| Half-life | 2 hours (range 1-4) for nicotine; terminal half-life 10-12 hours for cotinine; clinical context: short t½ requires frequent dosing. Half-life prolonged in hepatic impairment. |
| Protein binding | <5% (nicotine) bound to albumin; cotinine 15-20% bound |
| Volume of Distribution | 2-3 L/kg; extensive tissue distribution, crosses placenta and enters breast milk |
| Bioavailability | Gum: 50-80% (variable due to swallowing and technique); lozenge: 60-80%; transdermal: 80-90% |
| Onset of Action | Intravenous: immediate; buccal (gum): 15-30 minutes; transdermal: 2-4 hours |
| Duration of Action | Gum: 30-60 minutes; lozenge: 30-60 minutes; patch: 24 hours (steady state); clinical notes: peak effects in 1 hour after gum/lozenge, sustained plateau with patch. |
For smoking cessation, apply one 2 mg or 4 mg lozenge (mint) every 1-2 hours as needed for cravings, up to 15 lozenges per day. Use 4 mg lozenge if first cigarette is within 30 minutes of waking. Do not chew; allow to dissolve slowly (20-30 minutes). Frequency should be tapered after 6 weeks.
| Dosage form | GUM, CHEWING |
| Renal impairment | No specific dose adjustment is required for renal impairment; however, nicotine and its metabolites accumulate in severe renal impairment (eGFR <30 mL/min/1.73m²). Caution advised; use lowest effective dose. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A or B. For severe hepatic impairment (Child-Pugh class C), dose reduction is recommended due to reduced clearance; initiate with 2 mg lozenge and limit to 6-8 lozenges per day. |
| Pediatric use | Not approved for use in patients under 12 years of age. Weight-based guidelines not established. |
| Geriatric use | No specific dose adjustment required; however, elderly patients may have higher risk of adverse effects. Initiate with lowest dose (2 mg) and titrate based on tolerance and response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NICORETTE (MINT) (NICORETTE (MINT)).
| Breastfeeding | Nicotine is excreted in breast milk with an estimated milk-to-plasma (M/P) ratio of approximately 2–3. It can reach infant serum levels up to 3% of maternal dose. Potential effects on the infant include apnea, bradycardia, and gastrointestinal distress. The American Academy of Pediatrics considers nicotine replacement therapy (NRT) as relatively compatible with breastfeeding, but direct nicotine exposure from NRT is lower than from smoking. However, the safety of chronic use during lactation is not fully established; therefore, the lowest effective dose should be used, and infant monitoring is advised. |
| Teratogenic Risk | Nicotine is a known teratogen; first trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, low birth weight, and congenital anomalies including oral clefts and cardiovascular defects. Second and third trimester exposure can impair fetal brain development and cause fetal nicotine dependence. The risk is dose-dependent. Nicorette (mint) contains nicotine and should only be used in pregnancy if the benefit of smoking cessation outweighs the risks, as smoking itself is highly teratogenic. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to nicotine or any component of the product","Current smoking (do not use while smoking)","Pregnancy (absolute risk outweighs benefit, unless smoking cessation is critical)","Lactation (small amounts excreted in breast milk - avoid if possible)"]
| Precautions | ["Risk of nicotine toxicity in children and pets; keep out of reach","Caution in cardiovascular disease (recent MI, serious arrhythmias, unstable angina) - weigh risks","May cause allergic reactions including angioedema","Use caution in phaeochromocytoma and uncontrolled hyperthyroidism","Risk of seizures, especially in patients with history of seizure disorders"] |
Loading safety data…
| Fetal Monitoring | For pregnant or potentially pregnant women using Nicorette, monitor fetal growth via serial ultrasound, assess for signs of preterm labor, and evaluate for maternal hypertension or tachycardia. In the postpartum period, monitor the infant for nicotine toxicity: respiratory rate, heart rate, feeding patterns, and stool output. No specific laboratory monitoring is required, but consider cotinine levels if toxicity is suspected. |
| Fertility Effects | Nicotine has been shown to reduce fertility in both males and females. In women, it can alter menstrual function, impair ovulation, and decrease oviductal transport. In men, nicotine reduces sperm motility, count, and viability, and increases DNA damage. These effects are reversible upon cessation of nicotine use. Nicorette, as a nicotine delivery system, may similarly impair fertility. |